Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

548
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
548
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.4K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

281
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
281
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

426
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
426
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calix[4]resorcinarene-Based Porous Organic Cages: Synthesis and Applications.

Accounts of chemical research·2026
Same author

Analysis of the boundary load impact on porcelain insulators and DIC test.

Scientific reports·2026
Same author

Pillar-Layered Metal-Organic Frameworks Enabled by Pre-assembled Trianglsalen Macrocycles.

Inorganic chemistry·2026
Same author

Dibutyl phthalate affects glycerolipid metabolism and causes maternal impacts on the cladoceran Daphnia magna.

Journal of environmental sciences (China)·2026
Same author

Burden and Trends of Six Gynecological Diseases Among Chinese Women Aged 15-49 Years, 1990-2021: Evidence from GBD 2021.

International journal of women's health·2026
Same author

Mainland diversification and recent island lineages in the reduviid genus Tapirocoris: an integrative taxonomic framework with four new species.

Insect science·2026
Same journal

The sequential cohort randomized clinical trial: A study design for community-engaged clinical research in a rural American Indian community.

Contemporary clinical trials·2026
Same journal

Rationale, design, and statistical analysis plan for a randomized, double-blind, placebo-controlled trial of Limosilactobacillus reuteri to support mother-infant bonding and maternal socioemotional functioning in postpartum women at increased risk for postpartum depression.

Contemporary clinical trials·2026
Same journal

Effectiveness of clinical trial recruitment strategies in a safety-net hospital.

Contemporary clinical trials·2026
Same journal

Are older adult research participants representative of the general population? Results from 19 clinical studies at one academic research center.

Contemporary clinical trials·2026
Same journal

Multi-site feasibility of a web-based and telephone navigation intervention to connect lung cancer caregivers in community oncology settings with resources: Protocol for the WF-2301CD Caregiver Oncology Needs Evaluation Tool (CONNECT) trial.

Contemporary clinical trials·2026
Same journal

Rationale and design of a CArdiac rehabilitation program on the prevention of CardioTOXicity in breast Cancer patients undergoing treatment with anthracyclines and/or trastuzumab (CARPTOX-BC) trial: A randomized, active control group, open-label trial.

Contemporary clinical trials·2026
See all related articles

Related Experiment Video

Updated: Dec 1, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K

Statistical adaptation to oncology drug development evolution.

Mingxiu Hu1, Miao Yang1, Yi Liu1

  • 1Nektar Therapeutics, 360 Third Street, San Francisco, CA 94107, USA.

Contemporary Clinical Trials
|November 9, 2020
PubMed
Summary
This summary is machine-generated.

Cancer treatment has evolved from surgery, radiation, and chemotherapy to immunotherapy. Statistical methods are adapting to analyze immunotherapy trials, focusing on delayed effects and long-term outcomes for better drug development.

Keywords:
Delayed effectImmunotherapyLogrank testLong-term cure effectOncology drug developmentZmax test

More Related Videos

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.6K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Related Experiment Videos

Last Updated: Dec 1, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.6K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Traditional cancer treatments like surgery, radiation, and chemotherapy aim to directly eliminate cancer cells.
  • Recent advancements in cancer therapy include immunotherapies, which harness the patient's immune system to fight cancer long-term.
  • Immunotherapies offer potential cures for metastatic cancers, marking a significant shift in oncology treatment paradigms.

Purpose of the Study:

  • To describe the historical evolution of cancer drug development.
  • To explain the necessary adaptations in clinical trial designs and statistical methodologies for novel oncology treatments.
  • To highlight the importance of statistical analysis in evaluating immunotherapies.

Main Methods:

  • Review of historical cancer treatment modalities.
  • Discussion of current trends in oncology drug development, focusing on immunotherapies.
  • Exploration of statistical methodologies suitable for analyzing time-to-event data in immunotherapy trials, including Fleming-Harrington and Zmax tests.
  • Consideration of trial design adaptations for delayed and long-term effects characteristic of immunotherapies.

Main Results:

  • Cancer treatment has progressed from invasive "cut, burn, and poison" methods to immune system modulation.
  • Immunotherapies represent a revolutionary approach, potentially enabling long-term cancer remission and cures.
  • Statistical methods need to be updated to accurately reflect the unique efficacy profiles of immunotherapies, such as delayed onset and durable responses.

Conclusions:

  • Oncology drug development is continuously evolving, necessitating parallel advancements in clinical trial design and statistical analysis.
  • Adapting statistical approaches is crucial for efficiently evaluating novel immunotherapies and bringing them to patients.
  • Modern statistical tests can enhance the power of analyses for time-to-event data, especially when hazards are non-proportional.